Olema Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Even with a brief drop this week, the markets are showing strength this year, with the S&P 500 climbing 8%. However, there’s a big question on investors’ minds: Can this momentum keep up? David Kostin, Goldman’s chief US equity strategist, has given four scenarios for investor consideration: “(1) in a ‘catch up,’ the S&P 500 would end the year at 5800 (+12% from today), (2) in a ‘catch-down,’ the S&P 500 would fall to 4500 (-14%), (3) continued mega-cap exceptionalism would lift the index to 600

Multiple small-and mid-cap stocks have "exciting stories" to tell investors in 2021. One analyst recommends Olema Pharma, Morphic Holding, and Schrodinger The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies’ managing director Michael Yee says the valuations are not only justified but sustainable in 2021. ‘Exciting stories’ for 2021 While looking at the Biotech sector, it is important to separate the small group of COVID-19 vaccine makers from the overall biotech innovation thesis, Yee said Tuesday on CNBC’s “Closing Bell.�...